Skip to content

Identification and Detection of Peripheral Blood Biomarkers in Patients with Malignancy-Associated DVT: A Single-Center, Prospective, Observational Clinical Study Protocol

Identification and Detection of Peripheral Blood Biomarkers in Patients with Malignancy-Associated DVT: A Single-Center, Prospective, Observational Clinical

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600127122
Enrollment
Unknown
Registered
2026-06-25
Start date
2026-01-04
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignancy-associated lower-extremity deep vein thrombosis

Interventions

Gold Standard:Pathology?Venography
Index test:Candidate biomarker

Sponsors

The First Affiliated Hospital of Anhui Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Participants aged 18 years or older with a confirmed DVT and a clinical diagnosis of malignant tumor or benign tumor were eligible for inclusion.. 2.An anticipated follow-up period of at least 6 months is required. 3. Diagnosis of cancer-associated DVT was confirmed by medical history or other diagnostic tests related to malignant tumors;

Exclusion criteria

Exclusion criteria: 1. Participants who have received anticoagulation, immunosuppressive therapy, or hematologic system–related treatment within the last 3 months are excluded. 2.Participants who cannot be diagnosed as cancer-associated DVT based on medical history or other diagnostic indicators are excluded. 3. Participants with severe infection, autoimmune disease, or pregnancy are excluded. 4.Participants who have experienced brain infarction, myocardial infarction, or cerebrovascular accident within the last 3 months are excluded.5.Severe trauma within the past 4 weeks, recent major surgery, or other reliable ancillary examinations indicating contraindications lead to exclusion. 5.Severe trauma within the past 4 weeks, recent major surgery, or other reliable ancillary examinations indicating contraindications lead to exclusion. 6.Participants with coagulation disorders or severe cardiopulmonary insufficiency or severe dysfunction of other critical organs are excluded.

Design outcomes

Primary

MeasureTime frame
Differential expression levels of peripheral blood proteins between cancer-associated DVT patients and non-cancer DVT patients;

Secondary

MeasureTime frame
Diagnostic performance of candidate biomarkers (AUC, sensitivity, specificity);

Countries

China

Contacts

Public ContactBinshan Zha

The First Affiliated Hospital of Anhui Medical University

binszha2013@163.com+86 551 6323 6400

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jul 3, 2026